Angela Pistorio, Olaf Witt, Samantha Mascelli, Marcello Ravegnani, Maria Luisa Garrè, David T.W. Jones, Giovanni Morana, Alessandro Raso, Stefan M. Pfister, Valeria Capra, Dominique Figarella-Branger, Alessandro Consales, Armando Cama, Carole Colin, Claudia Milanaccio, Roberto Biassoni, Paolo Nozza, Dipartimento Testa, Collo e Neuroscienze, Istituto Giannina Gaslini, 16147 Genoa, Italy, Anatomia Patologica, Istituto Giannina Gaslini, 16147 Genoa, Italy, Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany, Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), IRCCS G. Gaslini, Servizio di Epidemiologia e Biostatistica, Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany, Neuroradiologia Istituto Giannina Gaslini, 16147 Genoa, Italy, Department of Pharmacological Sciences and Department of Biomolecular Sciences and Biotechnology, University of Milan, Molecular Medicine, Translational Medicine Department, Istituto Giannina Gaslini, 16147 Genoa, Italy, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Service d'Anatomo-Cyto-Pathologie et de NeuroPathologie [Hôpital de la Timone - APHM] (ACPNP), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centro di Neuro-Oncologia, Istituto Giannina Gaslini, 16147 Genoa, Italy, School of Medicine and Pharmacology, The University of Western Australia (UWA), Università degli Studi di Milano = University of Milan (UNIMI), and figarella-branger, dominique
// Samantha Mascelli 1 , Paolo Nozza 2 , David T.W. Jones 3 , Carole Colin 4 , Angela Pistorio 5 , Claudia Milanaccio 1 , Marcello Ravegnani 1 , Alessandro Consales 1 , Olaf Witt 6 , Giovanni Morana 7 , Armando Cama 1 , Valeria Capra 1 , Roberto Biassoni 8 , Stefan M. Pfister 3, 6 , Dominique Figarella-Branger 4, 9 , Maria Luisa Garre 10 , Alessandro Raso 1 1 Dipartimento Testa, Collo e Neuroscienze, Istituto Giannina Gaslini, 16147 Genoa, Italy 2 UOC Anatomia Patologica, Istituto Giannina Gaslini, 16147 Genoa, Italy 3 Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany 4 CRO2 UMR_S911, Inserm, Aix-Marseille Universite, 13385 Marseille, France 5 Epidemiologia, Biostatistica e Comitati, Istituto Giannina Gaslini, 16147 Genoa, Italy 6 Department of Paediatric Oncology, Haematology and Immunology, University of Heidelberg, Heidelberg, 69120 Heidelberg, Germany 7 Neuroradiologia Istituto Giannina Gaslini, 16147 Genoa, Italy 8 Laboratory Molecular Medicine, Translational Medicine Department, Istituto Giannina Gaslini, 16147 Genoa, Italy 9 APHM, Hopital de la Timone, Service d’Anatomie Pathologique et de Neuropathologie, 13385 Marseille, France 10 Centro di Neuro-Oncologia, Istituto Giannina Gaslini, 16147 Genoa, Italy Correspondence to: Samantha Mascelli, email: SamanthaMascelli@gaslini.org Keywords: low-grade gliomas, polymorphism, pilocytic astrocytoma, paediatric, TP53 Received: March 25, 2016 Accepted: May 10, 2016 Published: June 25, 2016 ABSTRACT Pilocytic astrocytoma and ganglioglioma may occur in inaccessible or surgically difficult areas. In case of incomplete resection, the availability of biological predictors of tumour progression could be particularly important. To this end, an analysis of p53 codon 72 polymorphism and assessment of its role as prognostic marker were performed. The status of the p53 Arg72Pro polymorphism was evaluated by pyrosequencing method in a multicenter cohort of 170 paediatric patients. Genotype/phenotype associations were investigated either by means of bivariate or multivariate analyses. In the partially resected pilocytic astrocytomas, the Arg/Arg variant predicts early tumour progression (median survival time: 23.1 months) and is associated with poor event-free survival ( p value = 0.0009). This finding remains true also in case of adjuvant therapies, with a 5-year event-free survival of 30.6% for cases with Arg/Arg variant vs. 78.7% for those with other genotypes. There is no association between ganglioglioma and the polymorphism. The assessment of Arg/Arg variant could improve the management of pilocytic astrocytoma. TP53 codon 72 analysis could distinguish low-risk cases, in which surgery could be conservative, from high-risk cases needing an aggressive surgery plan.